Generic Name: panobinostat
Drug Class: Chemotherapy Medications
Company: Novartis
Approval Status: Approved
Generic Version Available: No
Drug Indication
Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).
General Info
Farydak is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.
Clinical trials showed that Farydak in combination with other medications slows progression of multiple myeloma.
Dosage
Dosing Info:
Farydak is a pill taken every other day for two weeks followed by a week off. It is usually given for eight cycles, but may be continued in people with ongoing clinical benefit.
Side Effects
Common side effects include diarrhea, fatigue, nausea, swelling, decreased appetite, fever and vomiting. It can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential severe side effects include heart rhythm abnormalities and heart attack.
For More Info: https://www.us.farydak.com/
Co-Pay Program Info: https://securabio.com/patient-support-programs
Patient Assistance Program Info: https://securabio.com/patient-support-programs
Last Reviewed: September 18, 2018
